Top

Cancer Cell International

Published in:

Open Access 01-12-2023 | Melanoma | Research

It is not all about the alpha: elevated expression of p53β variants is associated with lower probability of survival in a retrospective melanoma cohort

Authors: Kira Groen, Luiza Steffens Reinhardt, Jean-Christophe Bourdon, Kelly A. Avery-Kiejda

Published in: Cancer Cell International | Issue 1/2023

Abstract

Background

Melanoma is the deadliest type of skin cancer and despite improvements in treatment outcomes, melanoma claimed 57,043 lives in 2020. In most malignancies, p53 mutation rates are above 50% and provide prognostic indications. However, in melanoma where less than a quarter of cases harbour a p53 mutation, the significance of the tumour suppressor may be questioned. Instead, p53 isoforms, which modulate p53’s canonical function, may be of greater clinical importance.

Methods

The expression of p53 isoforms was evaluated in 123 melanoma specimens by immunohistochemistry using p53 isoform-specific antibodies (DO-1, KJC8, KJC40, and KJC133). To determine whether TP53 mutations may be driving p53 isoform expression, TP53 was sequenced in 30 FFPE melanoma samples.

Results

The C-terminally truncated p53β isoforms (KJC8) were found to be the most highly expressed p53 isoforms compared to all other isoforms. Further, elevated KJC8 staining was found to correlate with reduced probability of melanoma-specific survival, while KJC40 staining (Δ40p53) positively correlated with reduced melanoma thickness. TAp53 isoforms (p53 retaining both transactivation domains, DO-1), were the second highest p53 isoforms expressed across all samples. Elevated DO-1 staining was also associated with worse survival outcomes and more advanced stages of cancer. Given that the isoforms are likely to work in concert, composite isoform profiles were generated. Composite biomarker profiles revealed that elevated TAp53 (DO-1) and p53β (KJC8) expression, accompanied by low Δ40p53 (KJC40) and Δ133p53 (KJC133) expression was associated with the worst survival outcomes. Supporting the lack of predictive biomarker potential of TP53 in melanoma, no clinicopathological or p53 isoform expression associations could be linked to TP53 status.

Conclusions

Given the lack of prognostic biomarker potential derived from TP53 status, this study highlights how p53 isoform expression might progress this field and, pending further validation, may provide additional information to treating oncologists that might be factored into treatment decisions.

Available only for authorised users

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J Clinicians. 2021;71(3):209–49.

Kastenhuber ER, Lowe SW. Putting p53 in context. Cell. 2017;170(6):1062–78.PubMedPubMedCentral

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4.PubMed

Avery-Kiejda KA, Bowden NA, Croft AJ, Scurr LL, Kairupan CF, Ashton KA, et al. P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation. BMC Cancer. 2011;11:203.PubMedPubMedCentral

Kichina JV, Rauth S, Das Gupta TK, Gudkov AV. Melanoma cells can tolerate high levels of transcriptionally active endogenous p53 but are sensitive to retrovirus-transduced p53. Oncogene. 2003;22(31):4911–7.PubMed

Houben R, Hesbacher S, Schmid CP, Kauczok CS, Flohr U, Haferkamp S, et al. High-level expression of wild-type p53 in melanoma cells is frequently associated with inactivity in p53 reporter gene assays. PLoS ONE. 2011;6(7): e22096.PubMedPubMedCentral

Loureiro JB, Abrantes M, Oliveira PA, Saraiva L. P53 in skin cancer: From a master player to a privileged target for prevention and therapy. Biochimica Et Biophys Acta (BBA) Rev Cancer. 2020;1874(2):188438.

Satyamoorthy K, Chehab NH, Waterman MJ, Lien MC, El-Deiry WS, Herlyn M, et al. Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells. Cell Growth Differ. 2000;11(9):467–74.PubMed

Zanon M, Piris A, Bersani I, Vegetti C, Molla A, Scarito A, et al. Apoptosis protease activator protein-1 expression is dispensable for response of human melanoma cells to distinct proapoptotic agents. Cancer Res. 2004;64(20):7386–94.PubMed

10.

Joruiz SM, Bourdon JC. p53 Isoforms: key regulators of the cell fate decision. Cold Spring Harb Perspect Med. 2016. https://doi.org/10.1101/cshperspect.a026039.CrossRefPubMedPubMedCentral

11.

Avery-Kiejda KA, Morten B, Wong-Brown MW, Mathe A, Scott RJ. The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome. Carcinogenesis. 2014;35(3):586–96.PubMed

12.

Steffens Reinhardt L, Groen K, Morten BC, Bourdon JC, Avery-Kiejda KA. Cytoplasmic p53β isoforms are associated with worse disease-free survival in breast cancer. Int J Mol Sci. 2022. https://doi.org/10.3390/ijms23126670.CrossRefPubMedPubMedCentral

13.

Boldrup L, Bourdon JC, Coates PJ, Sjostrom B, Nylander K. Expression of p53 isoforms in squamous cell carcinoma of the head and neck. Eur J Cancer. 2007;43(3):617–23.PubMedPubMedCentral

14.

Goldschneider D, Horvilleur E, Plassa LF, Guillaud-Bataille M, Million K, Wittmer-Dupret E, et al. Expression of C-terminal deleted p53 isoforms in neuroblastoma. Nucleic Acids Res. 2006;34(19):5603–12.PubMedPubMedCentral

15.

Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 2005;19(18):2122–37.PubMedPubMedCentral

16.

Ghosh A, Stewart D, Matlashewski G. Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol. 2004;24(18):7987–97.PubMedPubMedCentral

17.

Avery-Kiejda KA, Zhang XD, Adams LJ, Scott RJ, Vojtesek B, Lane DP, et al. Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clin Cancer Res. 2008;14(6):1659–68.PubMed

18.

Ozretić P, Hanžić N, Proust B, Sabol M, Trnski D, Radić M, et al. Expression profiles of p53/p73, NME and GLI families in metastatic melanoma tissue and cell lines. Sci Rep. 2019;9(1):1–13.

19.

Tadijan A, Precazzini F, Hanžić N, Radić M, Gavioli N, Vlašić I, et al. Altered Expression of Shorter p53 family isoforms can impact melanoma aggressiveness. Cancers. 2021. https://doi.org/10.3390/cancers13205231.CrossRefPubMedPubMedCentral

20.

Takahashi R, Giannini C, Sarkaria JN, Schroeder M, Rogers J, Mastroeni D, et al. p53 isoform profiling in glioblastoma and injured brain. Oncogene. 2013;32(26):3165–74.PubMed

21.

Zhang X, Groen K, Morten BC, Steffens Reinhardt L, Campbell HG, Braithwaite AW, et al. Effect of p53 and its N-terminally truncated isoform, Δ40p53, on breast cancer migration and invasion. Mol Oncol. 2022;16(2):447–65.PubMed

22.

Morten BC, Scott RJ, Avery-Kiejda KA. Comparison of the QuantiGene 2.0 assay and real-Time RT-PCR in the detection of p53 isoform mRNA expression in formalin-fixed paraffin-embedded tissues—a preliminary study. PLoS ONE. 2016;11(11):e0165930.PubMedPubMedCentral

23.

Kazantseva M, Eiholzer RA, Mehta S, Taha A, Bowie S, Roth I, et al. Elevation of the TP53 isoform Δ133p53β in glioblastomas: an alternative to mutant p53 in promoting tumor development. J Pathol. 2018;246(1):77–88.PubMedPubMedCentral

24.

Ewels P, Magnusson M, Lundin S, Käller M. MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics. 2016;32(19):3047–8.PubMedPubMedCentral

25.

Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Meth. 2009;41(4):1149–60.

26.

Budczies J, Klauschen F, Sinn BV, Győrffy B, Schmitt WD, Darb-Esfahani S, et al. Cutoff Finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. PLoS ONE. 2012;7(12): e51862.PubMedPubMedCentral

27.

Anbarasan T, Bourdon JC. The emerging landscape of p53 isoforms in physiology, cancer and degenerative diseases. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20246257.CrossRefPubMedPubMedCentral

28.

Gadea G, Arsic N, Fernandes K, Diot A, Joruiz SM, Abdallah S, et al. TP53 drives invasion through expression of its Δ133p53β variant. Elife. 2016;5:e14734.PubMedPubMedCentral

29.

Surget S, Khoury MP, Bourdon JC. Uncovering the role of p53 splice variants in human malignancy: a clinical perspective. Onco Targets Ther. 2014;7:57–68.

30.

Marcel V, Dichtel-Danjoy ML, Sagne C, Hafsi H, Ma D, Ortiz-Cuaran S, et al. Biological functions of p53 isoforms through evolution: lessons from animal and cellular models. Cell Death Differ. 2011;18(12):1815–24.PubMedPubMedCentral

31.

Steffens Reinhardt L, Zhang X, Groen K, Morten BC, De Iuliis GN, Braithwaite AW, et al. Alterations in the p53 isoform ratio govern breast cancer cell fate in response to DNA damage. Cell Death Dis. 2022;13(10):907.PubMedPubMedCentral

32.

Joruiz SM, Beck JA, Horikawa I, Harris CC. The Δ133p53 isoforms, tuners of the p53 pathway. Cancers. 2020. https://doi.org/10.3390/cancers12113422.CrossRefPubMedPubMedCentral

33.

Steffens Reinhardt L, Groen K, Zhang X, Morten BC, Wawruszak A, Avery-Kiejda KA. p53 isoform expression promotes a stemness phenotype and inhibits doxorubicin sensitivity in breast cancer. Cell Death Dis. 2023;14(8):509.PubMedPubMedCentral

34.

Marcel V, Fernandes K, Terrier O, Lane DP, Bourdon JC. Modulation of p53β and p53γ expression by regulating the alternative splicing of TP53 gene modifies cellular response. Cell Death Differ. 2014;21(9):1377–87.PubMedPubMedCentral

35.

Jesus ANB, Taha A, Wang D, Mehta PM, Mehta S, Reily-Bell A, et al. Increased expression of the Δ133p53β isoform enhances brain metastasis. Int J Mol Sci. 2023. https://doi.org/10.3390/ijms24021267.CrossRefPubMedPubMedCentral

36.

Arsic N, Gadea G, Lagerqvist EL, Busson M, Cahuzac N, Brock C, et al. The p53 isoform Delta133p53beta promotes cancer stem cell potential. Stem Cell Reports. 2015;4(4):531–40.PubMedPubMedCentral

37.

Lei J, Qi R, Tang Y, Wang W, Wei G, Nussinov R, et al. Conformational stability and dynamics of the cancer-associated isoform Δ133p53β are modulated by p53 peptides and p53-specific DNA. Faseb j. 2019;33(3):4225–35.PubMedPubMedCentral

38.

Ou Z, Yin L, Chang C, Peng J, Chen J. Protein interaction between p53 and Δ113p53 is required for the anti-apoptotic function of Δ113p53. J Genet Genomics. 2014;41(2):53–62.PubMed

39.

Anbarasan T, Bourdon J-C. The emerging landscape of p53 isoforms in physiology, cancer and degenerative diseases. Int J Mol Sci. 2019;20(24):6257.PubMedPubMedCentral

40.

Patel H, Yacoub N, Mishra R, White A, Yuan L, Alanazi S, et al. Current advances in the treatment of BRAF-mutant melanoma. Cancers. 2020;12(2):482.PubMedPubMedCentral

41.

Celesia A, Franzò M, Di Liberto D, Lauricella M, Carlisi D, D’Anneo A, et al. Oncogenic BRAF and p53 interplay in melanoma cells and the effects of the HDAC Inhibitor ITF2357 (Givinostat). Int J Mol Sci. 2023;24(11):9148.PubMedPubMedCentral

42.

Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD, et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Current Biol. 2005;15(3):249–54.

43.

Olivares-Illana V, Fåhraeus R. p53 isoforms gain functions. Oncogene. 2010;29(37):5113–9.PubMed

44.

Vieler M, Sanyal S. p53 isoforms and their implications in cancer. Cancers. 2018. https://doi.org/10.3390/cancers10090288.CrossRefPubMedPubMedCentral

45.

Morten BC, Wong-Brown MW, Scott RJ, Avery-Kiejda KA. The presence of the intron 3 16 bp duplication polymorphism of p53 (rs17878362) in breast cancer is associated with a low Delta40p53:p53 ratio and better outcome. Carcinogenesis. 2016;37(1):81–6.PubMed

46.

Steffens Reinhardt L, Groen K, Xavier A, Avery-Kiejda KA. p53 Dysregulation in Breast Cancer: Insights on Mutations in the TP53 Network and p53 Isoform Expression. Int J Mol Sci. 2023;24(12):10078.PubMedPubMedCentral

47.

Hofstetter G, Berger A, Fiegl H, Slade N, Zoric A, Holzer B, et al. Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer. Oncogene. 2010;29(13):1997–2004.PubMed

48.

Grover R, Ray PS, Das S. Polypyrimidine tract binding protein regulates IRES-mediated translation of p53 isoforms. Cell cycle (Georgetown, Tex). 2008;7(14):2189–98.PubMed

49.

Wei J, Noto J, Zaika E, Romero-Gallo J, Correa P, El-Rifai W, et al. Pathogenic bacterium Helicobacter pylori alters the expression profile of p53 protein isoforms and p53 response to cellular stresses. Proc Natl Acad Sci U S A. 2012;109(38):E2543–50.PubMedPubMedCentral

50.

Weingarten-Gabbay S, Khan D, Liberman N, Yoffe Y, Bialik S, Das S, et al. The translation initiation factor DAP5 promotes IRES-driven translation of p53 mRNA. Oncogene. 2013. https://doi.org/10.1038/onc.2012.626.CrossRefPubMed

51.

Powell DJ, Hrstka R, Candeias M, Bourougaa K, Vojtesek B, Fahraeus R. Stress-dependent changes in the properties of p53 complexes by the alternative translation product p53/47. Cell Cycle. 2008;7(7):950–9.PubMed

52.

Sharathchandra A, Lal R, Khan D, Das S. Annexin A2 and PSF proteins interact with p53 IRES and regulate translation of p53 mRNA. RNA Biol. 2012;9(12):1429–39.PubMed

53.

Solomon H, Sharon M, Rotter V. Modulation of alternative splicing contributes to cancer development: focusing on p53 isoforms, p53β and p53γ. Cell Death Differ. 2014;21(9):1347–9.PubMedPubMedCentral

54.

Bahmad HF, Cheaito K, Chalhoub RM, Hadadeh O, Monzer A, Ballout F, et al. Sphere-Formation assay: three-dimensional in vitro culturing of prostate cancer stem/progenitor sphere-forming cells. Front Oncol. 2018;8:347.PubMedPubMedCentral

55.

Kozovska Z, Gabrisova V, Kucerova L. Malignant melanoma: diagnosis, treatment and cancer stem cells. Neoplasma. 2016;63(4):510–7.PubMed

56.

Bruce WJ, Koljonen JL, Romanelli MR, Khan AU, Neumeister MW. Adjuvant and neoadjuvant therapeutics for the treatment of cutaneous melanoma. Clin Plast Surg. 2021;48(4):651–8.PubMed

57.

Fujita K, Mondal AM, Horikawa I, Nguyen GH, Kumamoto K, Sohn JJ, et al. p53 isoforms [Delta]133p53 and p53[beta] are endogenous regulators of replicative cellular senescence. Nat Cell Biol. 2009;11(9):1135–42.PubMedPubMedCentral

58.

Mondal AM, Horikawa I, Pine SR, Fujita K, Morgan KM, Vera E, et al. p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes. J Clin Invest. 2013;123(12):5247–57.PubMedPubMedCentral

59.

Sparrow LE, Soong R, Dawkins HJ, Iacopetta BJ, Heenan PJ. p53 gene mutation and expression in naevi and melanomas. Melanoma Res. 1995;5(2):93–100.PubMed

60.

Stein Y, Rotter V, Aloni-Grinstein R. Gain-of-Function Mutant p53: all the roads lead to tumorigenesis. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20246197.CrossRefPubMedPubMedCentral

61.

Tadijan A, Precazzini F, Hanžić N, Radić M, Gavioli N, Vlašić I, et al. Altered expression of shorter p53 family isoforms can impact melanoma aggressiveness. Cancers. 2021;13(20):5231.PubMedPubMedCentral

62.

Steffens Reinhardt L, Zhang X, Wawruszak A, Groen K, De Iuliis GN, Avery-Kiejda KA. Good cop, bad cop: defining the roles of Delta40p53 in cancer and aging. Cancers. 2020. https://doi.org/10.3390/cancers12061659.CrossRefPubMedPubMedCentral

63.

Steffens Reinhardt L, Groen K, Newton C, Avery-Kiejda KA. The role of truncated p53 isoforms in the DNA damage response. Biochim Et Biophys Acta Rev Cancer. 2023;1878(3):188882.

Title: It is not all about the alpha: elevated expression of p53β variants is associated with lower probability of survival in a retrospective melanoma cohort
Authors: Kira Groen
Luiza Steffens Reinhardt
Jean-Christophe Bourdon
Kelly A. Avery-Kiejda
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Melanoma
Melanoma
Published in: Cancer Cell International / Issue 1/2023
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-023-03083-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Loss of two-pore channel 2 function in melanoma-derived tumours reduces tumour growth in vivo but greatly increases tumour-related toxicity in the organism

Statins enhances antitumor effect of oxaliplatin in KRAS-mutated colorectal cancer cells and inhibits oxaliplatin-induced neuropathy

A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1

Nomogram prediction for the risk of venous thromboembolism in patients with lung cancer

Anterior gradient 2 induces resistance to sorafenib via endoplasmic reticulum stress regulation in hepatocellular carcinoma

Role of epithelial splicing regulatory protein 1 in cancer progression

Keynote webinar | Spotlight on antibody–drug conjugates in cancer